COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC:

Get the latest research information from NIH: Menu

OC000459 Bronchial Allergen Challenge

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT01056692
Recruitment Status : Completed
First Posted : January 26, 2010
Last Update Posted : January 26, 2010
Medicines Evaluation Unit, Manchester, UK
King's College Hospital NHS Trust
Information provided by:
Oxagen Ltd

Brief Summary:
OC0000459 reduces inflammation in the tissues in response to allergic stimuli in patients with asthma. This clinical trial, in mildly asthmatic patients, studies the effects of OC000459 and placebo on the asthmatic response to two known stimulants of the asthmatic response in the lungs, namely cat hair, pollen or house dust mite and methacholine.

Condition or disease Intervention/treatment Phase
Bronchial Asthma Drug: OC000459 Drug: Placebo Phase 2

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 20 participants
Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: Double
Primary Purpose: Treatment
Official Title: A Phase II Study of oc000459 in Subjects With Allergic Asthma; a Randomised, Double Blind, Two Way Balanced Crossover Comparing oc000459 With Placebo
Study Start Date : February 2006

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Asthma

Arm Intervention/treatment
Active Comparator: Active compound
OC000459 orally
Drug: OC000459
Capsules twice daily for 15 days

Placebo Comparator: Placebo
Placebo given orally
Drug: Placebo
Capsules twice daily for 15 days

Primary Outcome Measures :
  1. The primary endpoint is the diminution in the late asthmatic response to bronchial allergen challenge as measured by the AUC and the maximum of percentage reductions in FEV1 between 3 and 10 hours after allergen challenge. [ Time Frame: Primary outcome is measured after 15 days of treatment with active or placebo ]

Secondary Outcome Measures :
  1. Secondary biological activity endpoints include the diminution of the early asthmatic response to bronchial allergen challenge sputum eosinophilia, the methacholine PC20 after allergen challenge and exhaled NO pre- and post-allergen. [ Time Frame: These measures are examined after 15 days of treatment with either active or placebo ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years to 45 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Known history of asthma (intermittent wheezing, cough, dyspnoea responsive to inhaled short acting beta agonists).
  • FEV1 >65% of predicted on at least two occasions at screening.
  • At the screening allergen challenge, a decrease in FEV1 of ≥20% in the early asthmatic reaction and of ≥15% in the LAR to allergen on 3 separate occasions between 3-10hrs post allergen, 2 of which must be consecutive.
  • No steroid usage in the past 12 weeks.
  • Testing positive to skin prick challenge with at least one of the following allergens: house dust mite, pollen or cat hair within the previous 12 months.
  • Non smokers for a minimum of 6 months; less than 10 pack year history.

Exclusion Criteria:

  • Respiratory tract pathology other than allergic asthma.
  • Lower respiratory tract infection within 4 weeks prior to an allergen challenge.
  • Receipt of prescribed or OTC medication other than paracetamol or short acting inhaled beta agonists within 14 days of screening or of the first day of each dosing period.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT01056692

Layout table for location information
United Kingdom
King's College London School of Medicine
London, United Kingdom, SE5 9PJ
Medicines Evaluation Unit
Manchester, United Kingdom, M23 9LT
Sponsors and Collaborators
Oxagen Ltd
Medicines Evaluation Unit, Manchester, UK
King's College Hospital NHS Trust
Layout table for investigator information
Principal Investigator: David Singh, MD Medicines Evaluation Unit, Manchester, UK
Publications automatically indexed to this study by Identifier (NCT Number):
Layout table for additonal information
Responsible Party: Dr David Singh, Medicines Evaluation Unit, Manchester UK Identifier: NCT01056692    
Other Study ID Numbers: OC000459/004/05
First Posted: January 26, 2010    Key Record Dates
Last Update Posted: January 26, 2010
Last Verified: January 2010
Keywords provided by Oxagen Ltd:
bronchial allergen challenge
sputum eosinophiilia
Additional relevant MeSH terms:
Layout table for MeSH terms
Bronchial Diseases
Respiratory Tract Diseases
Lung Diseases, Obstructive
Lung Diseases
Respiratory Hypersensitivity
Hypersensitivity, Immediate
Immune System Diseases